Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Express Scripts
Moodys
Johnson and Johnson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PATANOL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Patanol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00609128 ↗ Effect of Olopatadine on Allergic Tear Mediators Completed National Eye Institute (NEI) N/A 2000-09-01 The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.
NCT00609128 ↗ Effect of Olopatadine on Allergic Tear Mediators Completed University of Wisconsin, Madison N/A 2000-09-01 The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.
NCT01119287 ↗ Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed Alcon Research Phase 4 2010-03-01 The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
NCT01435460 ↗ Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) Completed Bausch & Lomb Incorporated Phase 3 2010-08-01 This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).
NCT02478398 ↗ Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) Completed Merck Sharp & Dohme Corp. Phase 3 2015-07-20 The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration of short ragweed pollen allergen extract sublingual immunotherapy tablets to children 5 to 17 years of age, compared with placebo, will result in a significant reduction in the combination of rhinoconjunctivitis symptoms and medication use over the peak ragweed season (RS).
NCT03186755 ↗ Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Recruiting Université de Montréal Phase 4 2017-06-11 This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergic conjunctivitis in the pediatric population. Half of participants will receive Hylo-Dual, while the other half will receive Olopatadine treatment for 2 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Patanol

Condition Name

Condition Name for Patanol
Intervention Trials
Allergic Conjunctivitis 3
Rhinitis, Allergic, Seasonal 1
Seasonal Allergic Conjunctivitis 1
Allergic Eye Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Patanol
Intervention Trials
Conjunctivitis, Allergic 5
Conjunctivitis 5
Rhinitis, Allergic, Seasonal 1
Rhinitis, Allergic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Patanol

Trials by Country

Trials by Country for Patanol
Location Trials
United States 25
Canada 2
Croatia 1
Ukraine 1
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Patanol
Location Trials
Massachusetts 2
Texas 2
Wisconsin 2
Georgia 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Patanol

Clinical Trial Phase

Clinical Trial Phase for Patanol
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Patanol
Clinical Trial Phase Trials
Completed 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Patanol

Sponsor Name

Sponsor Name for Patanol
Sponsor Trials
University of Wisconsin, Madison 1
Alcon Research 1
Bausch & Lomb Incorporated 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Patanol
Sponsor Trials
Industry 4
Other 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Express Scripts
McKesson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.